In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
The FDA's rejection of ITM's radiopharma therapy sends shockwaves through the pharmaceutical industry.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Peak measured velocity The recorded velocity reached 14.
- Latest coverage observed Most recent article currently attached to this story cluster.
Source diversity sample: Endpoints News · AuntMinnie · cancernetwork.com · WBOC TV · TradingView · Fierce Pharma · STAT.
How this dossier is built: methodology · AI policy · corrections.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Where it stands
The FDA has rejected ITM's radiopharma therapy ¹⁷⁷Lu-edotreotide (ITM-11), which was anticipated to compete with Novartis' treatment. The FDA's decision came in the form of a Complete Response Letter, citing manufacturing concerns.
According to STAT, the FDA's decision was unexpected. The FDA's rejection is a setback for ITM, which had hoped to gain approval for the therapy.
The therapy was expected to rival Novartis' treatment, and its rejection could impact the competitive landscape of the radiopharma market.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (83% supported) Updated 20h ago.
The reporting (7)
- Manufacturing problems cited in FDA rejection of ITM's radiopharma drug Endpoints News · 1d ago
- ITM receives Complete Response Letter for ITM-11 AuntMinnie · 1d ago
- 177Lu-Edoterotide Handed CRL by FDA For GEP-NETs Treatment cancernetwork.com · 1d ago
- ITM Receives Complete Response Letter for ¹⁷⁷Lu-edotreotide (ITM-11) WBOC TV · 1d ago
- ITM Says FDA Issues Complete Response Letter For 177Lu-Edotreotide (ITM-11) NDA TradingView · 1d ago
- ITM cancer drug spurned by FDA over manufacturing qualms Fierce Pharma · 1d ago
- In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment STAT · 1d ago
Answered
What is ¹⁷⁷Lu-edotreotide (ITM-11)?
¹⁷⁷Lu-edotreotide (ITM-11) is a radiopharma therapy developed by ITM. It was expected to rival a treatment offered by Novartis.
Why was ¹⁷⁷Lu-edotreotide (ITM-11) rejected by the FDA?
The FDA rejected ¹⁷⁷Lu-edotreotide (ITM-11) over manufacturing concerns.
What is a Complete Response Letter?
A Complete Response Letter is issued by the FDA to inform a company that their application for a new drug cannot be approved in its present form.
Topics
Related trends
CEOs Pushed White House to Delay Ultra-Processed Food Policy
CEOs have intervened to delay the White House's ultra-processed food policy, which is now under review.
Silence Therapeutics aims at Takeda with new data in rare blood cancer
Silence Therapeutics' new data on a rare blood cancer drug could disrupt Takeda's market position
Taylor Farms Voluntarily Recalls Fresh Jalapeños Over Salmonella Concerns
Taylor Farms has recalled nearly 20 products containing jalapeños due to potential salmonella contamination.
Human "biology was never intended to handle" ultraprocessed foods, former FDA head David Kessler warns
The former FDA head warns that ultraprocessed foods may be overwhelming our bodies' natural defenses.
Patients in Illinois starting to receive experimental pancreatic cancer drug: ‘Game changer’
Patients in Illinois are among the first to receive a promising new drug for pancreatic cancer.
FDA approves Replimune melanoma drug previously rejected twice
Replimune's melanoma drug wins FDA approval on third attempt, but stock price falls.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.